New consortium launched to advance anti-tuberculosis science
To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions for TB patients worldwide, a new consortium of 30 partners from 13 countries has officially launched. The 7-year, €185 million project called UNITE4TB, aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active TB treatment regimens for drug-resistant and -sensitive TB.
Zendal and IAVI partner to advance the tuberculosis vaccine candidate MTBVAC into efficacy trials
Spanish biopharmaceutical company Biofabri and IAVI today announced their intention to partner on efficacy trials of the tuberculosis (TB) vaccine candidate MTBVAC. The only available TB vaccine, bacille Calmette-Guérin (BCG), does not prevent primary infection and has limited effectiveness at preventing pulmonary TB in adults, who, along with adolescents, are mainly responsible for spreading TB.
WHO issues position statement on TB clinical trial design
The World Health Organization published a position statement intended to support researchers and drug developers by outlining key clinical trial characteristics. This includes pharmacokinetic-pharmacodynamic modeling as well as recent advances in biomarker development.